Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 395Neoplasms 350Carcinoma, Non-Small-Cell Lung 313Prostatic Neoplasms 264Colorectal Neoplasms 236Lung Neoplasms 204Multiple Myeloma 163Pancreatic Neoplasms 147Ovarian Neoplasms 146Neoplasm Metastasis 141Leukemia, Myeloid, Acute 138Melanoma 118Squamous Cell Carcinoma of Head and Neck 100Carcinoma, Renal Cell 93Stomach Neoplasms 92Recurrence 92Lymphoma 91Lymphoma, Non-Hodgkin 89Endometrial Neoplasms 89Carcinoma, Hepatocellular 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 87Glioblastoma 85Brain Neoplasms 84Head and Neck Neoplasms 77Glioma 76Uterine Cervical Neoplasms 75Urinary Bladder Neoplasms 72Sarcoma 70Leukemia, Lymphocytic, Chronic, B-Cell 70Hematologic Neoplasms 68

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castrate Sensitive Prostate Cancer × 30 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡